Dr Stephen Assinder

Senior Lecturer
Physiology, School of Medical Sciences
Bosch Institute

K25 - Medical Foundation Building
The University of Sydney
NSW 2006 Australia

T: +61 2 9036 3614
F: +61 2 9351 8400
W: Related website
Related website

Research interests

The work of Andrology Research Group is concerned with two significant issues of male health, namely prostate disease and environmental endocrine disruption of male fertility.

Prostate Disease:

Prostate cancer is the most commonly diagnosed cancer in Australia, and is the second leading cause of cancer death in men. More than 2,700 men die of prostate cancer in Australia each year. It was estimated that in the year 2000, there were 513,000 new cases worldwide. Benign prostatic hyperplasia is the most common benign tumour in men, resulting in severe morbidity.

Research of the group is focused on:

1. Understanding how the loss of structural proteins involved in organization of the cell cytoskeleton contribute to the development of prostate cancer phenotypes.

2. Hormone regulation of prostate cell proliferation. In particular we are interested in how the hormones usually associated with females, namely oestrogen and oxytocin, are associated with abnormal growth of the prostate.

Endocrine disruption of male fertility:

It is of increasing concern that human sperm quality is declining. Many environmental factors have been implicated in this decline, including phytoestrogens. Since phytoestrogens were first associated with the disruption of mammalian fertility there has been considerable interest in their effects on sexual development and reproductive function. This is particularly pertinent given the increasing advocacy for the use of phytoestrogens as bioprotective agents against disease (eg. cardiovascular disease, prostate cancer). Work has recently demonstrated that exposure to phytoestrogen in adulthood can disrupt factors that determine fertility. In an attempt to understand the mechanisms involved, the group is developing transgenic models to determine the roles of oestrogen in spermatogenesis.


2013 | 2012 | 2011 | 2010 | 2009 | 2008


  • Ghalayini, M., Dong, Q., Richardson, D., Assinder, S. (2013), Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Bioscience Reports. 33(3), e00042. [Abstract]
  • Wee, N., Weinstein, D., Fraser, S., Assinder, S. (2013), The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease. International Journal of Biochemistry & Cell Biology. 45(5), 960-963. [Abstract]
  • Hua, S., Yao, M., Vignarajan, S., Witting, P., Hejazi, L., Gong, Z., Teng, Y., Niknami, M., Assinder, S., Richardson, D., Dong, Q. (2013), Cytosolic phospholipase A2alpha sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochimica et Biophysica Acta. 1831(6), 1146-1157. [Abstract]
  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013), Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer. 108(2), 409-419. [Abstract]
  • Velonas, V., Woo, H., Remedios, C., Assinder, S. (2013), Current status of biomarkers for prostate cancer. International Journal of Molecular Sciences. 14(6), 11034-11060. [Abstract]
  • Sánchez-Pérez, A., Brown, G., Malik, R., Assinder, S., Cantlon, K., Gotsis, C., Dunbar, S., Fraser, S. (2013), Rapid detection of haemotropic mycoplasma infection of feline erythrocytes using a novel flow cytometric approach. Parasites & Vectors. 6, 158. [Abstract]


  • Bower, N., Garcia de la Serrana, D., Cole, N., Hollway, G., Lee, H., Assinder, S., Johnston, I. (2012), STAC3 is required for myotube formation and myogenic differentiation in vertebrate skeletal muscle. Journal of Biological Chemistry. 287, 43936-43949. [Abstract]


  • Assinder, S., Cole, N. (2011), Does TGF-β induced formation of actin stress fibres reinforce Smad dependent TGF-β signalling in the prostate?. Medical hypotheses. 76(6), 802-4. [Abstract]
  • Assinder, S. (2011), TAGLN (transgelin). Atlas of Genetics and Cytogenetics in Oncology and Haematology. 15(6), 477-479.


  • Assinder, S., Au, E., Dong, Q., Winnick, C. (2010), A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer. Molecular Carcinogenesis. 49(6), 525-531. [Abstract]
  • Tom, N., Assinder, S. (2010), Oxytocin in health and disease. The international journal of biochemistry & cell biology. 42(2), 202-5. [Abstract]
  • Prasad, P., Stanton, J., Assinder, S. (2010), Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell and tissue research. 339(2), 337-47. [Abstract]
  • Tom, N., Assinder, S. (2010), Oxytocin: Recent developments. Biomolecular Concepts. 1(5-6), 367-380.


  • Assinder, S., Dong, Q., Mangs, H., Richardson, D. (2009), Pharmacological Targeting of the Integrated AKT, PTEN and TGF-{beta} Pathways in Prostate Cancer. Molecular Pharmacology. 75(3), 429-436. [Abstract]
  • Assinder, S., Stanton, J., Prasad, P. (2009), Transgelin: An actin-binding protein and tumour suppressor. The international journal of biochemistry & cell biology. 41(0), 482-6. [Abstract]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009), The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal. 417(2), 411-421. [Abstract]
  • Assinder, S. (2009), Oxytocin in the Pathophysiology of Prostate Cancer. In: Handbook of Oxytocin Research: Synthesis, Storage and Release, Actions and Drug Forms. (pp.155-170).United Kingdom: Nova Publishers.


  • Assinder, S. (2008), Oxytocin increases 5alpha-reductase activity of human prostate epithelial cells, but not stromal cells. The Prostate. 68, 115-21. [Abstract]
  • Nicholson, H., Assinder, S. (2008), Male gametogenesis. In: Textbook of Assisted Reproduction for Scientists in Reproductive Technology. (pp.3-30).Australia: VIVID Publishing.